mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.057 |
0.1 |
mRNA |
Crizotinib |
CCLE |
pan-cancer |
AAC |
-0.075 |
0.1 |
mRNA |
phenformin |
GDSC1000 |
pan-cancer |
AAC |
0.05 |
0.1 |
mRNA |
lenalidomide |
GDSC1000 |
pan-cancer |
AAC |
0.058 |
0.1 |
mRNA |
MS-275 |
CTRPv2 |
pan-cancer |
AAC |
0.054 |
0.1 |
mRNA |
BRD-K11533227 |
CTRPv2 |
pan-cancer |
AAC |
0.062 |
0.1 |
mRNA |
PF-543 |
CTRPv2 |
pan-cancer |
AAC |
0.062 |
0.1 |
mRNA |
Teniposide |
CTRPv2 |
pan-cancer |
AAC |
-0.064 |
0.1 |
mRNA |
selumetinib:piperlongumine (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.058 |
0.1 |
mRNA |
BRD4132 |
CTRPv2 |
pan-cancer |
AAC |
-0.062 |
0.1 |